Patents Assigned to BEIJING WISDOMAB BIOTECHNOLOGY CO., LTD
  • Anti-IL-4R antibody and use thereof
    Patent number: 11897960
    Abstract: Disclosed in the present application are an antibody or an antigen-binding portion thereof binding to human IL-4R, a polynucleotide encoding the antibody or antigen-binding portion thereof, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or vector, a method for preparing and purifying the antibody, and the use of the antibody or antigen-binding portion thereof.
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: February 13, 2024
    Assignees: Beijing Wisdomab Biotechnology Co., Ltd, Genrix (Shanghai) Biopharmaceutical Co. Ltd., Chongqing Genrix Biopharmaceutical Co., Ltd.
    Inventors: Zhigang Liu, Yulan Liu, Xiaobo Hao, Lei Jiang, Jingjing Guo
  • Bispecific antibody against rabies virus, and application thereof
    Patent number: 11773155
    Abstract: The present application provides a bispecific antibody against rabies virus, and an application thereof. The bispecific antibody comprises two antigen-binding fragments binding to different epitopes of G protein of rabies virus, and has rabies virus neutralization activity.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: October 3, 2023
    Assignees: Beijing Wisdomab Biotechnology Co., ltd, GENRIX (Shanghai) Biopharmaceutical Co., Ltd., Chongqing GENRIX Biopharmaceutical Co., Ltd.
    Inventors: Zhigang Liu, Xiaobo Hao, Yulan Liu, Jingjing Guo
  • Anti-human IL-17 monoclonal antibodies and use thereof
    Patent number: 10392436
    Abstract: The present application discloses a novel anti-human IL-17 monoclonal antibody obtained by phage antibody library screening and genetic engineering, or a functional fragment thereof, a polynucleotide encoding the monoclonal antibody or the functional fragment thereof, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or vector, a method for preparing and purifying the antibody, and use of the antibody or the functional fragment thereof.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: August 27, 2019
    Assignees: BEIJING BETTERMAB BIOTECHNOLOGY CO., LTD, BEIJING WISDOMAB BIOTECHNOLOGY CO., LTD, GENRIX (SHANGHAI) BIOPHARMACEUTICAL CO. LTD., CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD.
    Inventors: Zhigang Liu, Shijie Shen, Yulan Liu, Jingjing Guo, Xiaobo Hao